GenMark, Quidel Pace Decliners as Omics Tools/MDx Stocks Retreat in April | GenomeWeb

NEW YORK (GenomeWeb) – Many omics tools and molecular diagnostics firms saw their stock prices decline in April along with a general downturn for biotech stocks. 

The GenomeWeb Index, which tracks 31 firms operating in the omics and MDx space, declined more than 3 percent month over month. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.